Dihydropyrazolopyrimidinone derivatives
US8575179B2 · kind B2 · utility
10Cited by
0References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 9, 2009 |
| Grant date | Nov 5, 2013 |
| Priority date | — |
| Expiry date | Dec 29, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to compounds represented by the general formula (I) and the like. In the formula, Ar1 denotes an aryl or heteroaryl group which may have a substituent; R1 denotes a hydrogen atom, or denotes a C1-C6 alkyl, aryl, aralkyl or heteroaryl group which may have a substituent; R2 denotes an aralkyl group or a group represented by the formula (a); and R3 denotes a hydrogen atom or a C1-C6 alkyl group. The compounds of the invention have an excellent Wee1 kinase inhibitory effect, and therefore are useful in the field of medicine, especially in the field of treatment of various cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.